Eli Lilly and Company $LLY Shares Purchased by Northside Capital Management LLC

Northside Capital Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 3.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,894 shares of the company’s stock after buying an additional 618 shares during the period. Eli Lilly and Company makes up approximately 2.1% of Northside Capital Management LLC’s investment portfolio, making the stock its 12th largest holding. Northside Capital Management LLC’s holdings in Eli Lilly and Company were worth $25,061,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp grew its position in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after buying an additional 407,166 shares during the last quarter. Capital World Investors lifted its holdings in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after buying an additional 1,432,069 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on LLY shares. The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Sanford C. Bernstein raised their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Leerink Partners lifted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, Bank of America increased their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly filed six lawsuits against U.S. companies allegedly selling black-market versions of experimental obesity drug retatrutide. The action could help protect patients, preserve the drug’s future commercial value and limit counterfeit competition ahead of potential regulatory approval. Lilly sues six companies over alleged illegal sales of retatrutide
• Positive Sentiment: Lilly’s oral GLP-1 obesity drug Foundayo received its first approval outside the United States in the United Kingdom. The decision expands Lilly’s addressable market and strengthens its position against Novo Nordisk, although initial availability will be primarily through private prescriptions while NHS coverage is reviewed. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: An analyst upgrade and higher valuation targets added support to the stock’s bullish narrative. Lilly’s latest quarter also showed revenue growth of 47.7% to $22.97 billion and EPS of $8.38, well above the $6.40 consensus estimate, with fiscal 2026 EPS guidance of $35.50 to $36.50. Eli Lilly trading higher following analyst upgrade
• Neutral Sentiment: The retatrutide lawsuits are strategically positive but could involve legal expenses and do not change the drug’s regulatory status. Retatrutide remains experimental and has not yet been approved for sale.
• Negative Sentiment: Chief Accounting Officer Donald Zakrowski sold 2,000 shares worth about $2.37 million, following an executive vice president’s $5.95 million sale. Both transactions were made under pre-arranged Rule 10b5-1 plans, reducing their importance as indicators of management confidence, but the sales may weigh modestly on sentiment. Lilly chief accounting officer insider sale
• Negative Sentiment: Erste Group Bank trimmed its 2026 EPS estimate to $34.93 from $35.34, below Lilly’s guidance range and consensus expectations. With the stock trading at an elevated earnings multiple near 41 times, investors may be sensitive to any signs of slower growth or more conservative forecasts. Eli Lilly analyst estimates

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,212.96 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market capitalization of $1.14 trillion, a PE ratio of 40.70, a P/E/G ratio of 1.45 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $629.40 and a fifty-two week high of $1,249.45. The company has a fifty day moving average of $1,165.35 and a two-hundred day moving average of $1,049.90.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.33 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.